UK charities drive retinal dystrophy consortium

Article

UK sight loss charities RP Fighting Blindness and Fight for Sight are joining forces to drive a project that will accelerate understanding of the genetic causes of inherited retinal dystrophies (IRD).

UK sight loss charities RP Fighting Blindness and Fight for Sight are joining forces to drive a project that will accelerate understanding of the genetic causes of inherited retinal dystrophies (IRD).

The 'RP Genome Project' is being collaboratively funded by the two charities. It will bring together four leading genetic ophthalmology research centres: University of Leeds and St James Hospital Leeds, UCL Institute of Ophthalmology and Moorfields Eye Hospital, Manchester Academic Health Science Centre and Manchester Royal Eye Hospital, and University of Oxford and Oxford Eye Hospital. The programme is intended to facilitate greater collaboration between the centres and enhance the sharing of patient data that's essential in the development of clinical trials and future access to treatments.

The consortium will also later enable other such centres to join the programme and include patients for investigation, with a view to establishing a national patient data resource.

Professor Graeme Black, consultant in genetics and ophthalmology at Central Manchester University Hospital NHS Foundation Trust and The University of Manchester, and strategic director of the Manchester Centre for Genomic Medicine, is responsible for coordinating the consortium of centres.

"We are bringing together the UK's finest scientists and clinicians, who will be working more closely than ever before to investigate the causes, and potential treatments, for inherited retinal diseases," he said.

For more information visit www.rpfightingblindness.org.uk or fightforsight.org.uk.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.